Overall, the findings imply that orally administered AIII may be converted to sarsasapogenin by the gut microbiota to alleviate inflammatory diseases, such as colitis, by blocking the TLR4-NF-κB/MAPK signalling pathway while restoring the Th17/Treg cell balance [28]. Here, NFKB1 is linked to colitis.